HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes.

AbstractBACKGROUND:
Because no study has documented the angiogenic properties of hepatocyte growth factor (HGF) in a diabetes model, we examined the feasibility of gene therapy using HGF to treat peripheral arterial disease in diabetes.
METHODS AND RESULTS:
Because intramuscular injection of luciferase plasmid by the hemagglutinating virus of Japan (HVJ)-liposome method had much higher efficiency than injection of naked plasmid, we used the HVJ-liposome method to transfect the human HGF gene into the rat diabetic hindlimb model. As expected, transfection of human HGF vector resulted in a significant increase in blood flow as assessed by laser Doppler imaging and capillary density, even in the diabetes model, accompanied by the detection of human HGF protein. Interestingly, the degree of natural recovery of blood flow was significantly greater in nondiabetic rats than in diabetic rats. Thus, in an in vitro culture system, we further studied the molecular mechanisms of how diabetes delayed angiogenesis. Importantly, high-D-glucose treatment of endothelial cells resulted in a significant decrease in matrix metalloproteinase (MMP)-1 protein and ets-1 expression in human aortic endothelial cells. Similarly, high D-glucose significantly decreased mRNA and protein of HGF in endothelial cells. Downregulation of MMP-1 and ets-1 by high D-glucose might be due to a significant decrease in HGF, because HGF stimulated MMP-1 production and activated ets-1.
CONCLUSIONS:
Overall, intramuscular injection of human HGF plasmid induced therapeutic angiogenesis in a rat diabetic ischemic hindlimb model as a potential therapy for peripheral arterial disease. The delay of angiogenesis in diabetes might be due to downregulation of MMP-1 and ets-1 through a decrease in HGF by high D-glucose.
AuthorsY Taniyama, R Morishita, K Hiraoka, M Aoki, H Nakagami, K Yamasaki, K Matsumoto, T Nakamura, Y Kaneda, T Ogihara
JournalCirculation (Circulation) Vol. 104 Issue 19 Pg. 2344-50 (Nov 06 2001) ISSN: 1524-4539 [Electronic] United States
PMID11696476 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Blood Glucose
  • ETS1 protein, human
  • Ets1 protein, rat
  • Liposomes
  • Proto-Oncogene Protein c-ets-1
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-ets
  • Transcription Factors
  • Hepatocyte Growth Factor
  • Matrix Metalloproteinase 1
  • Glucose
Topics
  • Animals
  • Blood Glucose
  • Diabetes Mellitus, Experimental (chemically induced, complications, physiopathology)
  • Disease Models, Animal
  • Endothelium, Vascular (cytology, drug effects, metabolism)
  • Gene Transfer Techniques
  • Genetic Therapy (methods)
  • Genetic Vectors (administration & dosage, genetics)
  • Glucose (pharmacology)
  • Hepatocyte Growth Factor (administration & dosage, biosynthesis, genetics)
  • Hindlimb (blood supply, drug effects, physiopathology)
  • Humans
  • Injections, Intramuscular
  • Ischemia (complications, physiopathology, therapy)
  • Liposomes
  • Matrix Metalloproteinase 1 (metabolism)
  • Neovascularization, Physiologic (drug effects)
  • Proto-Oncogene Protein c-ets-1
  • Proto-Oncogene Proteins (metabolism)
  • Proto-Oncogene Proteins c-ets
  • Rats
  • Rats, Sprague-Dawley
  • Sendai virus (genetics)
  • Transcription Factors (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: